More on ALT
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $2.59 |
|
|||
| Open | $2.61 | ||||
| 52 Wk High | $54.24 | ||||
| 52 Wk Low | $48.35 | ||||
| Day High | $2.66 | ||||
| Day Low | $2.58 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 960,165 | ||||
- Altimmune (ALT) Reiterated at Market Outperform By Citizens After EASL Presentation
- Altimmune reports metabolic improvements for MASH drug pemvidutide
- Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026
- Altimmune to Participate in Upcoming Investor Conferences
- Altimmune presents phase 2b trial data showing pemvidutide liver benefits
- New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026
- Altimmune (ALT) PT Lowered to $20 at H.C. Wainwright
- Form SCHEDULE 13G/A Altimmune, Inc. Filed by: TANG CAPITAL MANAGEMENT LLC
- Altimmune (ALT) PT Lowered to $11 at Citizens on Increased Dilutive Shares in 10-Q Filing
- Form S-8 Altimmune, Inc.
Entities mentioned with ALT
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- 13G | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Show More...
